A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor Cancer
Status:
Recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
This is a first-in-human, open label, multicenter study to assess the safety, tolerability,
pharmacokinetics, pharmacodynamics, and the preliminary antitumor activity of TAS2940 in
patients with advanced or metastatic solid tumors who are not candidates for approved or
available therapies.